Inventor · disambiguated record
Todd Covey
Also filed as: COVEY TODD · COVEY TODD M
10 granted patents·35 pending applications·71 citations·filing 2001–2024
89Inventor score
Top patents by PatentIndex Score
45 records- 0196US11771696B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2021·Granted Oct 3, 2023·5 cites·12 claims
- 0295US9949971B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitorACERTA PHARMA BV·Filed 2015·Granted Apr 24, 2018·11 cites·26 claims
- 0394US11654143B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitorACERTA PHARMA BV·Filed 2021·Granted May 23, 2023·3 cites·21 claims
- 0493US10272083B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2015·Granted Apr 30, 2019·14 cites·20 claims
- 0591US11090302B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2019·Granted Aug 17, 2021·4 cites·10 claims
- 0686US12263164B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2023·Granted Apr 1, 2025·0 cites·18 claims
- 0784US10328080B2Therapeutic combination of PI3K inhibitor and a BTK inhibitorACERTA PHARMA BV·Filed 2014·Granted Jun 25, 2019·6 cites·15 claims
- 0884US2024216380A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2023·Application pending·0 cites
- 0982US2025090525A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2024·Application pending·0 cites
- 1081US9034257B2High throughput flow cytometry system and methodCOVEY TODD·Filed 2009·Granted May 19, 2015·13 cites·49 claims
- 1180US11166951B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitorACERTA PHARMA BV·Filed 2018·Granted Nov 9, 2021·2 cites·18 claims
- 1279US7348162B2Nucleic acids encoding fibroblast growth factor receptor-like proteins and uses thereofAMGEN INC·Filed 2001·Granted Mar 25, 2008·13 cites·11 claims
- 1373US2021346382A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 1469US2021322408A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 1569US2019314369A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 1665US2017102375A1Methods for determining the effects of compounds on jak/stat activityNODALITY INC·Filed 2016·Application pending·0 cites
- 1764US2019381044A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 1862US2016282335A1Methods for determining the effects of compounds on jak/stat activityNODALITY INC·Filed 2016·Application pending·0 cites
- 1962US2018369244A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 2062US2015110736A1Methods for determining the effects of compounds on jak/stat activityNODALITY INC·Filed 2014·Application pending·0 cites
- 2161US2014065633A1Methods for determining the effects of compounds on jak/stat activityFANTL WENDY J·Filed 2013·Application pending·0 cites
- 2259US2010209929A1Multiple mechanisms for modulation of jak/stat activityNODALITY INC A DELAWARE CORP·Filed 2010·Application pending·0 cites
- 2359US2018250400A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 2458US2018207154A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 2558US2015119288A1Kits for multiparametric phospho analysisNODALITY INC·Filed 2014·Application pending·0 cites
- 2657US2010030719A1Methods and apparatus related to bioinformatics data analysisCOVEY TODD M·Filed 2009·Application pending·0 cites
- 2756US2017231986A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 InhibitorACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 2856US2020069796A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 2956US2008044859A1Fibroblast Growth Factor Receptor-Like Molecules and Uses ThereofAMGEN INC·Filed 2007·Application pending·0 cites
- 3055US2017350911A1High throughput flow cytometry system and methodNODALITY INC·Filed 2017·Application pending·0 cites
- 3154US2017143712A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2017·Application pending·0 cites
- 3254US2017231995A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 3353US2010042351A1Methods and apparatus related to management of experimentsCOVEY TODD M·Filed 2009·Application pending·0 cites
- 3452US2019358235A1Therapeutic Combination of a PI3K Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 3552US2012276558A1Kits for multiparametric phospho analysisSOPER DAVID·Filed 2012·Application pending·0 cites
- 3651US2017224819A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 InhibitorACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 3749US2015309062A1High throughput flow cytometry system and methodNODALITY INC·Filed 2015·Application pending·0 cites
- 3848US2012215481A1Methods and apparatus related to management of experimentsCOVEY TODD M·Filed 2012·Application pending·0 cites
- 3948US2009269800A1Device and method for processing cell samplesCOVEY TODD·Filed 2009·Application pending·0 cites
- 4046US2003087384A1Fibroblast growth factor receptor-like molecules and uses thereofAMGEN INC A CORP OF THE STATE·Filed 2002·Application pending·0 cites
- 4143US2013129681A1Methods for diagnosing solid tumorsNODALITY INC·Filed 2012·Application pending·0 cites
- 4242US2017239351A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 InhibitorACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 4340US2014273089A1Fibroblast Growth Factor Receptor-Like Molecules and Uses ThereofSARIS CHRISTIAAN M·Filed 2013·Application pending·0 cites
- 4439US2014031308A1Benchmarks for normal cell identificationDIANE LONGO·Filed 2011·Application pending·0 cites
- 4537US2019376971A1Compositions and Methods for the Assessment of Drug Target Occupancy for Bruton's Tyrosine KinaseACERTA PHARMA BV·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Todd Covey files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →